Market Overview

Thomas W. Burns, CEO of Glaukos, Joins Avedro's Board of Directors


an ophthalmic pharmaceutical and medical device company and
the world leader in corneal remodeling, today announced that Thomas W.
Burns has been elected to its Board of Directors.

Mr. Burns has a proven track record of building successful medical
device and pharmaceutical businesses and creating successful new markets
in ophthalmology. Mr. Burns is President, Chief Executive Officer and a
member of the Board of Directors at Glaukos
, an ophthalmic medical technology company that pioneered
the Micro-Invasive Glaucoma Surgery (MIGS) clinical and commercial class
to transform the treatment of glaucoma. In his 16 years at Glaukos, Mr.
Burns has led the company from a small startup to the completion of an
initial public offering in June 2015 and beyond.

Mr. Burns has more than 25 years of direct ophthalmic management
experience, including over 20 years of general management experience
across a broad range of ophthalmic medical devices, ophthalmic
pharmaceuticals, drug delivery technologies, and surgical products. Over
his career, he has raised nearly $400M in private offerings and in the
public markets. Prior to Glaukos, Mr. Burns led Eyetech Pharmaceuticals
(acquired by OSI Pharmaceuticals) as President, Chief Operating Officer
and as a Director. He is currently Chairman of Dose Medical Inc.

"Tom's broad leadership experience in ophthalmology, specifically
growing Glaukos from a small startup to a successful public company,
will be of great value to Avedro, and we are pleased to welcome him as
an independent board member," said Reza Zadno, Ph.D., Chief Executive
Officer of Avedro. "We look forward to leveraging Tom's expertise as we
continue to develop innovative products that improve the corneal health,
visual acuity and quality of life of patients around the world."

"Since FDA approval in 2016, the company has demonstrated excellent
progress in securing insurance coverage for cross-linking and advancing
its next generation epi-on product candidate in a Phase 3 trial," said
Mr. Burns. "I am delighted to be joining Avedro's Board of Directors at
this exciting time and look forward to contributing to this company's
rapid growth."

Avedro, Inc.

Avedro is a privately held pharmaceutical and medical device company and
the world leader in corneal remodeling. Our patented cross-linking
technology, consisting of drug formulations and medical devices, are
approved for sale in numerous countries around the globe. We continue to
develop proprietary corneal remodeling products for the treatment of
keratoconus, corneal ectasia and for refractive correction as an
alternative to contacts and eyeglasses. Keratoconus and corneal ectasia
are rare and sight-threatening eye conditions in which the cornea
progressively thins and weakens causing the development of a cone-like
bulge and optical irregularity of the cornea which can result in
significant visual impairment. At Avedro, our mission is to produce and
deliver innovative, minimally invasive drugs and devices for corneal
remodeling to eyecare professionals around the world to improve
patients' vision and quality of life.

View Comments and Join the Discussion!